Industry Partnership Programme

Working together to improve liver health across the UK.

We work in partnership with industry to drive earlier diagnosis, improve care pathways, and ensure the patient voice is at the heart of liver health. Our Industry Partnership Programme brings together organisations committed to improving outcomes for people affected by liver disease. Through collaboration, we support system change, raise awareness, and deliver meaningful impact across the UK. All partnerships are governed by clear ethical guidelines, ensuring our independence is maintained at all times.

The following companies have provided funding to the British Liver Trust to be an industry partner in 2026.

Our partners

Aquilant

Aquilant is a healthcare company focused on advancing diagnostics and therapies, with a commitment to innovation in liver disease management. Through dedication to early detection and improved patient outcomes, Aquilant collaborates with Hisky Medical, leveraging partnership and expertise to deliver cutting edge solutions that support clinicians and enhance care pathways.

Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need.

Ipsen

At Ipsen, we are deeply committed to people living with rare liver diseases. We invest for the long term in scientific innovation, partnership with the hepatology community, and meaningful support for patients and families—working together to change the trajectory of rare liver disease and improve lives.

Madrigal

Madrigal is delighted to be an Industry Partner as we are focused on delivering novel therapeutics for MASH (metabolic dysfunction-associated steatohepatitis), a serious liver disease with high unmet medical need. Starting from a small group of researchers, Madrigal is now established in the USA and growing internationally including a UK team.

Norgine and Alfasigma

Norgine and Alfasigma are international pharmaceutical companies dedicated to improving people’s lives across a wide range of health conditions. Together, we are committed to supporting people affected by liver disease and are proud to be partners with the British Liver Trust.

Novo Nordisk

Novo Nordisk have provided funding to the British Liver Trust to be an industry partner in 2026.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease.

Siemens Healthineers

Siemens Healthineers provides innovative tools to meet the evolving needs of your chronic liver disease patients.

With a comprehensive portfolio of both in vivo and in vitro solutions, such as the Enhanced Liver Fibrosis (ELF™) Test, we can help transform care delivery in chronic liver disease.

We would like to thank all of our corporate partners for their ongoing support.